Predicting lymphoma treatment response with computer analysis
Part of Blood & lymphatic, Cancer clinical trials.
This study is testing whether a computer program that looks at MRI scans or biopsy tissue can predict how well your lymphoma will respond to first-line chemotherapy. It is not a drug trial, but a way to improve treatment planning by using your existing medical information.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You need a confirmed diagnosis of extranodal natural killer/T-cell lymphoma (a type of lymphoma often in the nose or face).
- You must be scheduled to receive your first standard treatment, which includes chemotherapy based on asparaginase (a type of drug) with or without radiation.
- You must have either a contrast-enhanced MRI of the nasopharynx (area behind the nose) or tissue slides from a biopsy available for the study team to review.
- You should not have a history of other cancers.
- You must be able to understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (PD-1 antibody, which helps your immune system fight cancer) and radiation therapy for people with early-stage nasal-type NK/T-cell lymphoma. It aims to see if this approach is safe and effective as a first treatment.
This study will look at information from people with non-Hodgkin lymphoma who are getting CAR-T cell therapy (a treatment that uses your own immune cells to attack cancer). The goal is to create tools that help doctors predict how well the treatment will work and what side effects might happen, so they can better care for patients.
This study tests whether a blood test (ctDNA) can help doctors see how well treatment is working for people with a type of brain lymphoma (PCNSL) who are getting their first treatment with a cure in mind.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This study tests whether patients with a specific type of blood cancer (NK/T-cell lymphoma) in the nose or sinuses who have responded well to chemotherapy can be safely treated with reduced radiation doses instead of standard high-dose radiation. The goal is to reduce side effects while maintaining effective treatment.
This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.
Hear when a new Natural Killer/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.